August 28, 2002Haemophilia
Guidelines for the diagnosis and management of von Willebrand disease in Italy
Population
Patients with von Willebrand disease (vWD)
Design
Guideline
Authors
Discussion
Loading...
Member takes
Implication
Tailors vWD therapy by subtype in daily practice; extends prior evidence into standardized national guidelines.
Key Points
- To establish standardized guidelines for the phenotypic diagnosis, molecular classification, and therapeutic management of von Willebrand disease subtypes.
- Outlined diagnostic protocols based on measurements of plasma and platelet von Willebrand factor (vWF), vWF-platelet receptor interactions, and multimeric structure analysis.
- Evaluated subtype-directed treatment pathways involving desmopressin, virus-inactivated factor VIII/vWF plasma concentrates, and adjunctive therapies.
- Desmopressin serves as the primary treatment for type 1 disease (representing approximately 70% of cases), successfully correcting factor VIII and vWF levels as well as bleeding time.
- Patients with type 3 and severe forms of type 1 and type 2 disease require replacement therapy with virally inactivated plasma concentrates containing factor VIII and vWF.
- Platelet concentrates and adjunctive desmopressin provide secondary therapeutic options when plasma concentrates fail to fully correct prolonged bleeding time.
Structured PICO
P
Population
Patients with von Willebrand disease (vWD)
I
Intervention
Desmopressin, plasma concentrates containing FVIII and vWF, or platelet concentrates
O
Outcome
Correction of haemostasis defects (abnormal intrinsic coagulation and abnormal platelet adhesion)
These Italian guidelines outline the diagnosis and management of von Willebrand disease, highlighting desmopressin for type 1 and plasma concentrates for severe or type 3 disease.
Cite This Study
Federici et al. (2002) studied this question.